[go: up one dir, main page]

WO2024263911A3 - Methods for the synthesis and linearization of peptidomimetic macrocycles - Google Patents

Methods for the synthesis and linearization of peptidomimetic macrocycles Download PDF

Info

Publication number
WO2024263911A3
WO2024263911A3 PCT/US2024/035013 US2024035013W WO2024263911A3 WO 2024263911 A3 WO2024263911 A3 WO 2024263911A3 US 2024035013 W US2024035013 W US 2024035013W WO 2024263911 A3 WO2024263911 A3 WO 2024263911A3
Authority
WO
WIPO (PCT)
Prior art keywords
linearization
synthesis
methods
peptidomimetic macrocycles
macrocycles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/035013
Other languages
French (fr)
Other versions
WO2024263911A2 (en
WO2024263911A9 (en
Inventor
Justin KIM
Elaine FOWLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of WO2024263911A2 publication Critical patent/WO2024263911A2/en
Publication of WO2024263911A9 publication Critical patent/WO2024263911A9/en
Publication of WO2024263911A3 publication Critical patent/WO2024263911A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are methodologies for the macrocyclization and linearization of peptides.
PCT/US2024/035013 2023-06-22 2024-06-21 Methods for the synthesis and linearization of peptidomimetic macrocycles Pending WO2024263911A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363522477P 2023-06-22 2023-06-22
US63/522,477 2023-06-22

Publications (3)

Publication Number Publication Date
WO2024263911A2 WO2024263911A2 (en) 2024-12-26
WO2024263911A9 WO2024263911A9 (en) 2025-03-13
WO2024263911A3 true WO2024263911A3 (en) 2025-04-10

Family

ID=93936253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/035013 Pending WO2024263911A2 (en) 2023-06-22 2024-06-21 Methods for the synthesis and linearization of peptidomimetic macrocycles

Country Status (1)

Country Link
WO (1) WO2024263911A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344519A1 (en) * 2012-02-07 2015-12-03 Nanyang Technological University Method of synthesizing peptides, proteins and bioconjugates
US20190169234A1 (en) * 2016-08-11 2019-06-06 The United States Of America, As Represented By The Secretary, Dept, Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
US20210061860A1 (en) * 2011-12-28 2021-03-04 Chugai Seiyaku Kabushiki Kaisha Peptide-compound cyclization method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210061860A1 (en) * 2011-12-28 2021-03-04 Chugai Seiyaku Kabushiki Kaisha Peptide-compound cyclization method
US20150344519A1 (en) * 2012-02-07 2015-12-03 Nanyang Technological University Method of synthesizing peptides, proteins and bioconjugates
US20190169234A1 (en) * 2016-08-11 2019-06-06 The United States Of America, As Represented By The Secretary, Dept, Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BECHTLER, C ET AL.: "Macrocyclization strategies for cyclic peptides and Peptidomimetics", RSC MEDICINAL CHEMISTRY, vol. 12, no. 8, 29 June 2021 (2021-06-29), pages 1325 - 1351, XP093297490, DOI: 10.1039/d1md00083g *
FOWLER, E ET AL.: "Chemically revertible molecular clasps: Hydroxamic acid-mediated peptide macrocyclization and linearization", CHEM, vol. 10, no. 2, 8 February 2024 (2024-02-08), pages 730 - 745, Retrieved from the Internet <URL:https://doi.org/10.1016/j.chempr.2023.12.003> *
JOSE, B ET AL.: "Toward an HDAC6 inhibitor: synthesis andconformational analysis of cyclic hexapeptide hydroxamic acid designed from a-tubulinsequence", BIOORGANIC AND MEDICINAL CHEMISTR Y, vol. 12, no. 6, 15 March 2004 (2004-03-15), pages 1351 - 1356, DOI: 10.1016/j.bmc. 2004.01.01 4 *
MILLER, MJ: "Syntheses and Therapeutic Potential of Hydroxamic Acid Based Siderophores and Analogues", CHEMICAL REVIEWS, vol. 89, 1989, pages 1563 - 1579, XP002537315, DOI: 10.1021/CR00097A011 *
OLLIVIER, N ET AL.: "A simple and traceless solid phase method simplifies the assembly of large peptides and the access to challenging proteins", CHEMICAL SCIENCE, vol. 8, 1 August 2017 (2017-08-01), pages 5362 - 5370, DOI: 10.1039/c7sc01912b *
SINATRA, L ET AL.: "Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs", ANGEWANDTE CHEMIE INTERNATIONAL E ITION, vol. 59, no. 50, 7 December 2020 (2020-12-07), pages 22494 - 22499, DOI: 10.1002/anie.202006725 *

Also Published As

Publication number Publication date
WO2024263911A2 (en) 2024-12-26
WO2024263911A9 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
WO2022235870A8 (en) Ras inhibitors for the treatment of cancer
WO1998002441A3 (en) Non immunosuppressive antifungal rapalogs
WO1999018206A3 (en) Human cancer antigen ny eso-1/cag-3 and gene encoding same
CA2365697A1 (en) Improved methods for recombinant peptide production
ZA202213704B (en) Automotive cargo/tray cover assembly
WO2024263911A3 (en) Methods for the synthesis and linearization of peptidomimetic macrocycles
WO2024249299A3 (en) Ras inhibitors
EP4289480A3 (en) Macrocyclic broad spectrum antibiotics
CA3242658A1 (en) Gamma delta t-cell-binding polypeptides and uses thereof
WO2025080946A3 (en) Macrocyclic ras inhibitors
WO2024192308A3 (en) Anti-cd28 compositions
WO2006113898A3 (en) Pif tetrapeptides
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
Wessjohann et al. Macrocyclic peptoids: N-alkylated cyclopeptides and depsipeptides
WO2006034480A3 (en) Sulfonamide bicyclic compounds
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
DE602004025730D1 (en) Angiontensin converting enzyme hemmendes peptid
AU2003299038A1 (en) Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity
EP4219523A3 (en) Crystalline dipeptides useful in the synthesis of elamipretide
AU2002361275A1 (en) Airbag comprising a variable-surface ventilation area
Lee et al. Synergistic effect of a novel cyclic pentadepsipeptide, neoN-methylsansalvamide, and paclitaxel on human multidrug resistance cancer cell lines
WO2024249555A3 (en) Filter media and related foam forming methods
CA2257803A1 (en) Non immunosuppressive antifungal rapalogs
WO2023196932A3 (en) Isolating active t-cell cars from bulk transduced human t-cells
WO2024186859A3 (en) Anti-tl1a antibody compositions and methods of treatment for sarcoidosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24826730

Country of ref document: EP

Kind code of ref document: A2